Hualan biological h7n9 vaccine completed preclinical study
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Hualan biology announced on January 7 that the h7n9 influenza vaccine developed by Hualan biological vaccine Co., Ltd., the holding subsidiary of the company, passed the on-site verification of drug registration and development of Henan food and Drug Administration on March 3 and was accepted by Henan food and drug administration Hualan biological yesterday closed at 30.20 yuan, up 5.37% It is understood that Hualan biological vaccine Co., Ltd., a subsidiary of Hualan biological holding company, obtained the h7n9 influenza vaccine research and development strain from the laboratory recognized by the World Health Organization on May 27, 2013, and officially launched the development of h7n9 influenza vaccine The announcement said that the company's h7n9 influenza vaccine product clinical research was accepted, indicating that the product has completed pre clinical research and entered the registration and application process According to the relevant national registration laws and regulations, the product will be reviewed by the State Food and drug administration after receiving the clinical research application, and the clinical trial approval document will be issued after passing the review The announcement also said that there was some uncertainty about the review time and results After passing the review, the clinical trial approval document will be issued and the clinical trial will be conducted according to the requirements The results of the clinical trial are also uncertain The clinical study of h7n9 influenza vaccine was accepted, which will not affect the company's recent performance.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.